Tremendous progress has been made in developing animal models for addictions, new treatments based on these models and testing these in patients with drug and alcohol dependence. We will review the most current research and state-of-the-art treatment for tobacco, alcohol, and other drugs of abuse and provide a framework for understanding current progress, limitations, and hope for the future.

By participating in this activity, attendees will be able to:

1. List major illnesses associated with obesity;
2. Discuss the epidemiology of obesity and overweight; and
3. Assess current theories, current treatment approaches-including minimally invasive surgery-and experimental approaches that have resulted from tests concluding that highly palatable, erotic and exotic foods act in the brain as a drug of abuse.

The session will provide participants with recent clinical trial data on therapeutics for the treatment of ADHD. In addition the symposium will focus on recognizing, reducing, and addressing stimulant abuse and diversion.

This activity is supported by an educational grant from Eli Lilly and Company.

This activity is sponsored by CME LLC. Veritas Institute for Medical Education, Inc. is the content provider.

While Substance Use Disorders have been primarily thought of as those involving chemical substances like tobacco or alcohol , more recently process addictions have been studied . Once the DSM 3 diagnostic scheme was changed to accommodate cocaine and minimize withdrawal or abstinence, gambling and sexual compulsivity have been studied and suggested to be addictions. These process addictions have much neurobiology and phenomenology in common with chemical addictions and this construct may be especially helpful in understanding the obesity epidemic and logical public health and treatment approaches.

Upon the completion of this activity, participants will be able to:

1. Review current epidemiological data on substance abuse disorders.
2. Review examples of common co-occurring disorders such as tobacco smoking and alcohol and depression.
3. List and Discuss diagnostic and treatment issues for co-occurring alcohol and tobacco-related illnesses.

Psychiatrists face a daunting task every day- diagnosing patients using an imperfect diagnostic manual, limited data and external pressures. Problems with diagnosis can impact treatment outcomes and clinician liability. Tools used in forensic psychiatry may improve diagnostic validity and reliability in clinical psychiatric practice. This session will review some of the problems we face in psychiatric diagnosis as well as a practical comparison of how clinical and legal decision makers use "evidence," explore uncertainty and avoid pitfalls. The participants will identify pitfalls and potential remedies to a sample case.

Upon the completion of this activity, participants will be able to:

1. Illustrate reliability of several DSM-IV diagnoses;
2. Compare clinical and legal approaches to "the evidence" and decision making; and
3. Identify tools that can enhance clinical diagnosis and management.

Upon completion of this activity, participants will be able to:

1. Understand how the menstrual cycle and perimenopause can affect psychiatric symptoms;
2. Understand how to modify psychopharmacologic treatment for premenstrual and perimenopausal symptoms;
3. Consider other clinical interventions for premenstrual and perimenopausal psychiatric symptoms

Bipolar disorder presents significant challanges to patients and their mental health and medical treatment team. Accurate diagnosis is essential to prevent making the situation worse. Treatment is complicated with ever changing treatment needs and goals.

By participating in this session, learners will be able to:

1. More accurately diagnose and successfully manage BD;
2. Utilize current advances in the use of combination versus monotherapy to optimize relapse prevention in the acute and long-term management of BD;
3. Identify strategies to optimize individual patient management of BD including related psychiatric and medical comorbidities and improve adherance rates;
4. Understand the role of antidepressants in the treatment of BD.

The session will provide participants with strategies for the management of adolescents with depression.

This activity is supported by an educational grant from Forest Laboratories, Inc.

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC.  The Institute for Continuing Healthcare Education is the content provider.

The session will provide participants with practical strategies for the diagnosis, treatment, and long term management of patients with schizophrenia.

12:15 - 12:45 p.m. Lunch
12:45- 2:15 p.m. Symposium

This activity is supported by an educational grant from Eli Lilly and Company.
This activity is sponsored by CME LLC. CME Outfitters is the content provider.

Upon the completion of this activity, participants will be able to:

1. Understand how pregnancy and the postpartum period affect the course and expression of mood disorders;
2. Understand the risks of untreated symptoms of mood disorders during pregnancy and postpartum;
3. Understand the risks of antidepressant and mood-stabilizing medications during pregnancy and postpartum, and prescribing practices that can minimize risks

Fibromyalgia syndrome affects 3-5% of the population and is the second most common presenting complaint in rheumatology. Primary care providers have difficulty caring for patients with fibromyalgia due to a wide array of pain and non-pain complaints including headache, abdominal pain, irritable bladder, jaw pain, insomnia, numbness and difficulty concentrating as well as others. Many of the presenting complaints may be psychologic in nature, but the underlying disease is distinct from the presenting depressive and anxiety symptoms. Sorting the myriad complaints and providing structure can be lifesaving for patients with fibromyalgia and is best treated by those skilled in psychology.

At the end of this activity, attendees will be able to:

1. Describe the current science about the pathophysiology of fibromyalgia syndrome;
2. Help the referring provider to manage the pain and psychosocial issues; and
3. Treat patients with pharmacologic and nonpharmacologic options.

Psychosocial support is an important aspect of HIV/AIDS care which enables people to function during overwhelmingly adverse circumstances and problems caused by HIV and AIDS.

By participating in this activity, attendees will be able to:

The session will provide participants with insight into insomnia management through discussions of assessment, treatment implications, and patient education strategies.

7:00-7:30 a.m. Breakfast
7:30-9:00 a.m. Symposium

This activity is supported by an educational grant from sanofi-aventis U.S.
This activity is sponsored by CME LLC. MediCom Worldwide, Inc. is the content provider.

Although close to 70% of all individuals with dementia suffer from Alzheimer's disease, there are still many other critically important subtypes of dementia that must be recognized by the clinician. This symposium will provide a broad definition of dementia and then focus on some of the most important medically-induced subtypes and how to recognize them. Subtypes to be covered include normal pressure hydrocephalus, dementias due to human prion diseases and HIV infection, traumatic brain injury, and dementias that result from toxic exposures such as to alcohol or heavy metals.

After Participating in this activity participants will be able to:

1. Discuss the entire spectrum of non-Alzheimer dementia subtypes
2. List what diagnostic signs point to a potential medically-induced form of dementia.
3. Discuss diagnosis and treatment of the following dementia subtypes: A) Normal pressure hydrocephalus.
4. Human prion diseases.
5. HIV associated dementia.
6. Dementia due to traumatic brain injury(e.g., dementia pugilistica).
7. Dementia due to ETOH and other toxic exposures. F) Dementia due to neurodegenerative diseases (e.g., multiple sclerosis).

Many experts say that the key to treating patients with agitation, aggression and dangerousness is to understand the factors that lead to this behavior and the treatments that are currently available.

By participating in this activity, attendees will be able to:

1. Discuss the etiology of agitative and aggressive feeling and dangerous behavior, and explore how various forms of psychiatric comorbidity increase the likelihood of such behavior;
2. Recognize the effective ways to conduct accurate risk assessments; and
3. Identify various integrated treatments, including cognitive behavioral and other skill-based interventions, to address such behavior.

Treating patients who suffer from Anorexia and/or Bulimia can cause psychiatrists and psychotherapists tremendous frustration or great satisfaction. Successful treatment of Eating Disorders requires a complete understanding of the multiple etiologies involved, the psychotherapies required and the sophisticated use of psychotropic medications. We will focus in this session on the keys optimizing clinical outcomes and achieving remission based upon the biopsychosocial etiology of these disorders. We will identify the factors that result in failure and frustration, as well as the keys to successfully reach appropriate treatment goals.

By participating in this activity, learners will be able to:

1. Understand the multimodal treatment necessary for the successful treatment of these biopsychosocial disorders.
2. Enhance their ability to successfully utilize cognitive/behavioral psychotherapeutic techniques within a dynamic understanding of Anorexia and Bulimia.
3. Update their ability to successfully utilize psychopharmacologic agents to treat Eating Disorders.

Forensic psychiatry is an emerging area of specialization in psychiatry and it is important for general psychiatrists to familiarize with this area to help in their interface with the legal system.

By participating in this activity, attendees will be able to:

1. Discuss the commonly encountered psychiatric problems in correctional centers;
2. To become familiar with the prevalence of mental illness in Correctional facilities and to understand the complexities of assessment and treatment of the mentally ill in this setting; and
3. Identify the legal challenges practitioners face.

The psychiatric consultant is often asked to help manage the MOST CHALLENGING demented patients. Often , these patients have Lewy Body Dementia or FrontoTemporal Dementia. Learn how to recognize and treat these conditions with actual patient videos which demonstrate key findings.

Upon the completion of this activity, participants will be able to:

1. Discuss the diagnosis and clinical presentation of Lewy Body Dementia and Frontotemporal Dementia;
2. Describe the pathophysiological mechanisms associated with dementia;
3. Review the nonpharmacological and pharmacological treatments for various dementia

While we attempt to make evidence-based decisions, the evidence in Psychiatry is incomplete and contradictory. Psychiatry is usually practiced behind closed doors in 1 to 1 confidential patient interactions. We want to learn how our psychiatric colleagues make difficult psychiatric decisions and treatment recommendations, but we have few opportunities to do so. Do they prescribe antidepressants for bipolar depression? or give benzodiazepines to patients with histories of substance abuse? How do they choose between augmentation options? Etc. When, Why and How do they make these and other complex treatment decisions? Join us in this stimulating interactive session as we utilize computerized response systems to explore these treatment questions and dilemmas. Learn, engage and participate with us. Bring your own cases, questions and treatment dilemmas.

By participating in this session, learners will be able to:

1. Learn how fellow psychiatric colleagues approach challenging treatment decisions in Mood and Anxiety Disorders.
2. Recognize the need for treatment decisions to be based on scientific evidence and clinical experience and acumen.
3. Enhance your ability to successfully treat Mood and Anxiety Disorders.

The session will provide participants with practical tools for the continuity of care for patients with schizophrenia.

This activity is supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC

This activity is jointly sponsored by the Indiana University School of Medicine and CME LLC. CME Outfitters is the content provider.

The session will provide participants strategies and reinforcement in dose titration, multimodal treatment, and long-term treatment adherence for patients with ADHD.

12:15 - 12:45 p.m. Lunch
12:45- 2:15 p.m. Symposium

This activity is supported by an educational grant from McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC. Veritas Institute for Medical Education Inc. is the content provider.

The session will provide participants with strategies for improving the management of comorbid depression as well as chronic pain and other physical symptoms.

12:15PM-12:45 p.m. Lunch
12:45-2:15 p.m. Symposium

This activity is supported by an educational grant from Eli Lilly and Company.

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC. The Institute for Continuing Healthcare Education is the content provider.

The evidence base for pharmacotherapy of PTSD has grown by leaps and bounds in the past 10 years. Early studies of amitriptyline and phenelzine showed some promise for treatment of PTSD. But sample sizes were small and larger-scale studies have not been conducted. Only one class of drugs, the selective serotonin reuptake inhibitor (SSRIs) has members of the class FDA-approved for PTSD. Numerous large, multi-center trials of SSRIs (and, more recently, several large trials with dual norepinephrine serotonin reuptake inhibitors [NSRIs]) conclusively demonstrate their short- and intermediate-term efficacy, but response rates are modest and the optimal duration of treatment is unclear. Furthermore, the efficacy of SSRIs in some populations (e.g., combat veterans with PTSD) has been questioned. As awareness of the prevalence and seriousness of PTSD has increased, so has the impetus to develop new and better treatments. Several other classes of medications, including anticonvulsants, atypical antipsychotics, and adrenergic agents (e.g., prazosin) have shown promise in relatively small studies for either monotherapy or adjunctive use. For some medications, large randomized controlled trials (RCTs) have been negative (e.g., the anticonvulsant tiagabine), whereas for others such trials are either ongoing (e.g., prazosin and risperidone) or have yet to be conducted (e.g., lamotrigine). A role for combined psychotherapy and pharmacotherapy of PTSD will be discussed.

Upon the completion of this activity, particpants will be able to:

1. List FDA approved treatments for posttraumatic stress disorder (PTSD).
2. Identify the different classes of psychotropic agents that may be useful in the treatment of PTSD.
3. Discuss the limitations of the available evidence base for PTSD pharmacotherapy and of the need for more studies and better therapeutics.

Upon the completion of this activity, participants will be able to:

1. Recognize patients with environmental sensitivities by asking a few screening questions.
2. Help the patient determine what environmental factors are or have potentially affected their health. Focusing on mold at home or work as a common culprit.
3. Recognize adrenal insufficiency, dysautonomia, mitochondrial compromise and chemical sensitivity in your patients and obtaining proper referral for these conditions in your area.

Both psychiatric and nonpsychiatric clinicians tend to underutilize screeners and rating instruments in their busy practices. This is an error worth rectifying expeditiously for the following reasons: use of screeners and rating instruments can actually improve outcomes, it can be very time efficient and many quality tools are available for no charge. This workshop will show videos of a few clinical scenarios and discuss what tools might have been appropriate to use. Copies of noncopyrighted screeners and rating instruments, appropriate for both psychiatric and nonpsychiatric settings, will be made available to participants. A toolkit filled of screeners and rating instruments will be brought to the workshop to show participants how they can create one for their own use.

By participating in this activity, attendees will be able to:

1. Recognize the many noncopyrighted tools available for clinician use covering a range of psychiatric disorders;
2. Define these tools that are very time efficient and improve diagnostic yield; and
3. Describe how to choose the right tool and how to score them.

The session will provide participants with education on the proper screening, diagnosis, and treatment of ADHD in children, adolescents, and adults.

7:00-7:30 a.m. Breakfast
7:30-9:00 a.m. Symposium

This educational activity is supported by an independent medical educational grant from Shire.
This activity is sponsored by CME LLC. Veritas Institute for Medical Education, Inc. is the content provider.

Psychiatrists are asked to render opinions and help in the management and treatment of a number of conditions which etiology may be primarily neurological, but its manifestations clearly psychiatric. Delirium is a transient, reversible organic mental syndrome caused by dysfunction in cerebral metabolism, characterized by an acute or subacute onset. Features of delirium include disturbance of consciousness, change in cognition, perceptual disturbances, global cognitive impairment, attentional abnormalities, increased or decreased psychomotor activity, and sleep-wake cycle disruption. Alcohol, medication intoxication, and withdrawal stages will be given special attention, as possible and common causes of delirium. The inappropriate treatment usually leads to improper treatment, thus delaying appropriate management.

Upon the completion of this activity, participants will be able to:

1. Understand the pathophysiology of delirium;
2. Understand the research-based, effective treatment options for delirium, including the use of atypical antipsychotic and other novel agents.
3. Learn research proven preventing techniques.

This course takes attendees on a provocative journey into the nature of happiness and the search for a novel framework for conceptualizing human nature - the human matrix. Practical ramifications for unstalling stalled treatment planning, enhancing the therapeutic alliance, preventing suicide, and creating a "tough resiliency" in both patients and clinicians are described in detail with clinical case examples.

By participating in this activity, attendees will be able to:

1. 1) Explain the concept of the human matrix model in everyday clinical practice, from engaging patients to treatment planning;
2. Discuss a unique definition of happiness and its implications for nurturing a resilient and "tougher happiness" and a more powerful style of treatment planning; and
3. Apply the principles of the "Human Matrix Model" for treatment planning, including healing matrix effects, damaging matrix effects, and the Red Herring Principle.

The best examination of a patient's neurocognitive status is a careful history and includes a clinical assessment that looks for variations from normal changes in a patient's neuroanatomy and records specific findings.

By participating in this activity, attendees will be able to:

List the primary domains of the neurocognitive mental status exam. 2) Employ simple, effective clinical tests to probe brain function. 3) Utilize systematic cognitive screening to confidently diagnose common dementia syndromes in geriatric patients.

The very common problem of partnered women who lose their desire for sexual behavior (HSDD) is addressed by understanding the nature of sexual desire, psychological intimacy, women's biology and the frequent transitions that occur within their lives. HSDD is an active arena of pharmacological research.

Upon the completion of this activity, participants will be able to:

1. Understand the individual, interpersonal, biological, and cultural aspects of sexual desire problems and their solutions.
2. Take a thorough history to estimate the patient's sexual desire situation.
3. Separate HSDD in women with ovarian function and those who are menopausal.
4. Appreciate the differences between a disorder model and a problem model.

The session will provide participants with strategies for improving rates of remission for major depressive disorder (MDD), including treatment resistant depression, along with combination and augmentation strategies for depression with atypical antipsychotics.

This activity is supported by an educational grant from Bristol-Myers Squibb and Otsuka America Pharmaceutical, Inc.

This activity is jointly sponsored by The Albert Einstein College of Medicine with Montefiore Medical Center and CME LLC. The Institute for Continuing Healthcare Education is the content provider.

Medication adherence can be a major challenge in patient care. This course will cover ten specific, practical and easily adopted interviewing techniques to improve medication adherence. These techniques are derived from the highly acclaimed motivational strategy known as the "medication interest model."

By participating in this activity, attendees will be able to:

1. Apply techniques such as the "inquiry into lost dreams" and the "trap-door question";
2. Identify the challenges in medication adherence by understanding how and why patients weigh the pros and cons of taking medications; and
3. Demonstrate the principles and applications of the medication interest model in a sophisticated fashion to a variety of difficult clinical situations.

Upon completion of this activity, participants will be able to:

1. Detect and diagnose Alzheimer's disease (AD) using DSM-IV criteria, APA & AAN practice guidelines;
2. Utilize clinical information to differentiate AD from other cognitive disorders;
3. Optimally manage patients using both behavioral and pharmacological techniques.

This course provides an overview of a clinical approach to diagnosis, evaluation and management of autonomic disorders.

By participating in this activity, attendees will be able to:

1. Discuss the clinical cases of orthostatic hypotension, orthostatic intolerance, autonomic neuropathies and disorders of sweating;
2. Discuss patient care by highlighting the ways by which the clinician can provide useful consultations and effectively manage patients suffering from autonomic disorders; and
3. Formulate a differential diagnosis and offer a treatment plan for patients with common and less common varieties of autonomic dysfunction.

Public outrage has justifiably ensued when convicted sex offenders who are released from prison commit subsequent sexual assaults.  At least seventeen states currently allow for the indeterminate civil commitment (i.e., locked psychiatric placement) of those sex offenders assessed as dangerous once they have completed their prison terms. These SVP statutes have engendered controversy both on constitutional and ethical grounds. All the DSM-IV-TR system can provide is a catalog of the specific mental disorders.  But which ones should count towards SVP civil commitment?

Upon the completion of this activity, participants will be able to:

1. Identify why twenty states have passed statutes mandating long term civil psychiatric commitment for sexually violent predators who are about to be released from prison.
2. List the legal and ethical difficulties that make this one of the most controversial areas in all of mental health practice.
3. Differentiate how well or poorly different DSM diagnoses fit into the statutory definition of mental disorder that triggers sexual predator civil commitment proceedings.

This is meditation's moment. From the cover of Time Magazine to the coffee table discussions of morning talk shows, meditation has acquired near mythic status both as an avenue to personal fulfillment and as a universal solvent against a dizzying array of diseases, mental and physical. However, despite increasing evidence that meditation may confer health benefits, significant gaps remain in our understanding of how meditation alters mind-body functioning to promote emotional and physical well-being. By providing a state-of-the-art update on what we do and do not know about meditation and meditation and mental health - with a focus on depression - this presentation will provide clinicians with information essential for thinking about how to incorporate meditation into their work with patients. The first talk in this program will provide an overview of research findings regarding mental health benefits of meditation, with a focus on rigorously examining areas of remaining uncertainty. The second talk will drill down deeper into a particular style of meditation - compassion meditation - to explore how this type of meditation may modulate deleterious stress responses relevant to health. The program will conclude with a chance for audience members to get a first hand sense of compassion meditation through a brief guided meditation.

At the end of this program, participants should be able to:

1. Describe the most important unanswered research questions regarding how to best apply meditation to mental illness.
2. Describe the different types of meditation practices that appear to offer the most promise as health interventions.
3. Describe how meditation practices may improve central nervous system, stress and immune functioning in ways likely to benefit mental and physical disease.
4. Describe what is known from the research literature regarding the effect of meditation on depression and anxiety in medically healthy and medically ill individuals.
5. Describe strategies for implementing meditation into clinical practice.

Upon the comletion of this activity, participants will be able to:

1. Define depression;
2. Outline causes and features of late life depression and discuss the known treatment modalities;
3. Assess therapy outcomes and how to improve these and;
4. Describe the need for maintenance therapy.

In 1984, Libby Zion died of a fatal drug interaction, and her death led to our present system of residency workplace hourly restrictions. Despite these changes, would a well-rested clinician be able to recognize and prevent her death today?

By participating in this activity, attendees will be able to:

1. Recognize clinically relevant drug interactions;
2. Utilize a framework and teaching tool to predict those patients most at risk for serotonin syndrome and other drug interactions; and
3. Describe the cytochrome P450 system.

Pain is one of the most common reasons patients seek medical attention and a symptom encountered by every physician.  According to American Pain Society estimates, 50 million people are partially or totally disabled by pain and 45% of all Americans seek care for persistent pain at some point in their lives.  Neuropathic pain can be especially difficult to diagnose and treat. In this session, advances in the understanding of the causes of common neuropathic pain syndromes will be reviewed, and treatment options will be addressed.

As a result of participation, attendees will:

1. Be able to better recognize the onset of neuropathic pain.
2. Have a better understanding of a range of treatment options.
3. Will be better able to understand pain physiology and its ramifications.

This lecture will try to offer help in early detection, ways to conceptualize the disorder for families, and will emphasize the role of the practitioner to coordinate the many services and therapies needed. It will also emphasize how to talk about alternative therapies which may be questionable and how to treat comorbid symptoms. It should provide an approach to the patient who is early in diagnosis to help shape family attitudes toward constructive outcomes.

By participating in this session, attendee will be able to

1. List why there is a need for early autism interventions.
2. Recognize the necessity of initiating treatment immediately once a diagnosis of autism is suspected.
3. Recognize the early and unique signs of the autistic spectrum disorder in order to begin intervention.
4. Diagnose co-morbid problems which may respond to medication in autistic spectrum disorders.
5. Evaluate the role of a physician in directing parents and patients through the complexities of services required.

Though we all have a personality, a disorder exists only when personality traits have become so extreme, inflexible, and maladaptive that they markedly impair functioning and get the person in the same kind of trouble over and over again. It's Differentiation from normalcy will be discussed along with classification and corresponding treatment techniques, including: psychodynamic, cognitive, behavioral, interpersonal, and supportive.

Upon the completion of this activity, participants will be able to:

1. Describe the adaptive value of personality traits, how these survived via natural selection, and how to support them in helping patients cope with medical and psychiatric illness.
2. Distinguish personality disorders from Axis I conditions.
3. List several cognitive, behavioral, psychodynamic, supportive, and paradoxical approaches to the treatment personality disorders.

Part 1 of this 2-part course is titled "Five Secrets for Uncovering Hidden and Taboo Material." This informative and insightful talk discusses innovative techniques for increasing validity while exploring sensitive material such as suicidal ideation.

By participating in this activity, attendees will be able to:

1. Recognize the following five interviewing techniques for increasing validity: the behavioral incident, shame attenuation, gentle assumption, symptom amplification and denial of the specific;
2. Discuss the theory behind the use of these five techniques for uncovering valid information when exploring sensitive areas such as domestic violence, substance abuse histories and antisocial behavior; and
3. Describe and flexibly weave the above five validity techniques into effective methods of uncovering sensitive material while maintaining a powerful engagement.

Upon the compleion of this activiy, participants will be able to:

1. Describe the typical study design strategies used for the approval of a new antipsychotic in the United States and the European Union;
2. List the newly approved (and not approved) medications for the treatment of schizophrenia, and how they differ from current therapies;
3. Describe how the deconstruction of schizophrenia into endophenotypes and syndromes has stimulated a new generation of pharmacotherapeutic research and;
4. List novel possible drug therapies that appear to work via glutamate/glycinergic.

This talk explores the ongoing concerns about the increase in the popularity of a socially designated class of drugs known as "club drugs."

By participating in this activity, attendees will be able to:

1. Discuss the major categorization of club drugs and their pharmacological properties;
2. Identify the clinical and psychiatric manifestations of club drugs; and
3. Recognize available treatment approaches and harm reduction and prevention strategies.

This Lecture will outline the current thinking about Tourette syndrome since it often includes co-morbid ADHD, OCD, and Anxiety Disorders. The make up of this trinity will be discussed and the ramification of making this diagnosis, as well as impart on insurability, and the natural cause of the disorder. Medication use for symptoms in the context of the comorbid problems will be discussed.

By participating in this education activity, participants will be able to:

1. List the symptoms of Tourette's syndrome and differentiate the types of tics and movements which are often associated with this syndrome.
2. Recognize the potentiality for co-morbid diagnoses like ADHD and OCD.
3. Discuss the characteristics of a proper evaluation and also appreciate what not to do.
4. List resources to help patients and families once a diagnosis is made.
5. Understand the role of medications in treating the tics as well as the co-morbidities.

Part 2 of this 2-part course is titled "An Innovative Method for Eliciting Suicidal Ideation-the Chronological Assessment of Suicide Events." This informative and insightful talk discusses the practical application of the interview strategies for eliciting suicidal ideation and behavior in different psychiatric settings.

By participating in this activity, attendees will be able to:

1. Recognize the role of 4 specific interviewing techniques for improving the validity of elicited suicidal ideation while decreasing errors of omission and optimizing engagement;
2. Define the theory and practical application of a specific interview strategy for the elicitation of suicidal ideation and behaviors: the Chronological Assessment of Suicide Events (CASE approach); and
3. Discuss and flexibly utilize the above approach as a sensitive and rapid method of uncovering suicidal ideation and intent in a busy clinic or hospital setting.

Upon the completion of this activity, participants will be able to:

1. Describe the relative risk of comorbid substance abuse with other psychiatric syndromes.
2. Identify the available pharmacological agents for treatment of dual-diagnosis patients and medication treatment for substance dependence disorders.
3. Discuss the difficulties relating to the treatment and the harm reduction model vs. the abstinence model for dual-diagnosis patients.

Sexual excesses, particularly among men, have been known to exist since antiquity. The rise of the Internet and its exploding technologies have created frequent requests by wives and patients themselves for help with the loss of control over sexual behaviors. While not yet a DSM diagnostic category, the treatment of sexual addiction syndromes require a sophisticated clinical knowledge of sexual and general mental disorders.

Upon the completion of this activity, participants will be able to:

1. To be able to interact with patients without countertransference moral revulsion.
2. To be able to focus on the sexual excesses as the clinical problem rather than the associated psychopathology.
3. To understand the allure of pornography for normal individuals and for those with sexual excesses.

Does "Motion', that is, exercise have a place in our treatment armamentarium? This is a question all clinicians have frequently asked of themselves. The last decade of clinical and animal research has revealed surprising powerful positive effects of exercise on mood disorders. We now know that exercise affects brain volume, inflammatory cytokines, and the autonomic system. Clinical research data also points to exercise's powerful anti-depressant effects. In light of these exciting findings, this seminar is aimed at providing clinicians the research findings, as will as provide attendees with tools on how to "prescribe" exercise to their patients. Clinicians will be provided with tools to assist them in implementing an exercise prescribing program in their practices.

Upon the completion of the this activity, participants will be able to:

1. Develop an scientifically and data based appreciation of the complex neurobiology of exercise's positive effects on  on mood.
Examine the clinical, randomized data of exercise treatment in mood disorder and develop practical skills in applying this information to clinical care of patients.